While Novo Nordisk (NVO) may have lost Metsera (MTSR) to Pfizer (PFE), CEO Mike Doustdar doesn’t plan to give up on dealmaking any time soon, Eric Pfanner, Aaron Kirchfeld, and Naomi Kresge of Bloomberg reports. Novo will continue to look for opportunities in obesity, diabetes, and other comorbidities associated with these diseases, people familiar with the situation told Bloomberg.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle
- Metsera enters deal to be acquired by Pfizer for up to $86.25 per share
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- Novo Nordisk to Lower Drug Prices in U.S. Starting 2026